Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M von Lilienfeld-Toal

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Annals of the Rheumatic Diseases|June 15, 2004
An unusual presentation of a common diseaseM von Lilienfeld-Toal, S Merkelbach-Bruse, F L Dumoulin
BMC Medical Ethics|October 18, 2024
Perioperative medication therapy for Muslim patients in Germany undergoing oncological surgery: a retrospective studyAysun Tekbaş, M von Lilienfeld-Toal, F Sayrafi, et al.
Der Pneumologe|March 28, 2020
[Pneumonia in immunocompromised patients]A Moeser, C Lange, M von Lilienfeld-Toal, et al.
Annals of Hematology|February 16, 2013
Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)S Neumann, S W Krause, G Maschmeyer, et al.
Annals of Hematology|December 6, 2001
Small bowel obstruction in acute myelogenous leukemia: stenosis or paralysis?M von Lilienfeld-Toal, O Ebert, I Theuerkauf, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 31, 2006
Change of procalcitonin predicts clinical outcome of febrile episodes in patients with hematological malignanciesM von Lilienfeld-Toal, A Schneider, K Orlopp, et al.
ESMO Open|April 12, 2025
Letter re: Ethnic origin in cancer clinical trials: overrated or understated?-A comprehensive analysis of cancer clinical trials leading to FDA and EMA approvals between 2020 and 2022M von Lilienfeld-Toal, S Agkatsev, A Glasmacher, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|September 6, 2005
An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patientsA Glasmacher, M von Lilienfeld-Toal, S Schulte, et al.
Infection|January 15, 2008
An audit of efficacy and toxicity of teicoplanin versus vancomycin in febrile neutropenia: is the different toxicity profile clinically relevant?C Hahn-Ast, A Glasmacher, A Arns, et al.
Clinical and Experimental Immunology|June 1, 2006
Activated gammadelta T cells express the natural cytotoxicity receptor natural killer p 44 and show cytotoxic activity against myeloma cellsM von Lilienfeld-Toal, J Nattermann, G Feldmann, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Annals of the Rheumatic Diseases|June 15, 2004
An unusual presentation of a common diseaseM von Lilienfeld-Toal, S Merkelbach-Bruse, F L Dumoulin
BMC Medical Ethics|October 18, 2024
Perioperative medication therapy for Muslim patients in Germany undergoing oncological surgery: a retrospective studyAysun Tekbaş, M von Lilienfeld-Toal, F Sayrafi, et al.
Der Pneumologe|March 28, 2020
[Pneumonia in immunocompromised patients]A Moeser, C Lange, M von Lilienfeld-Toal, et al.
Annals of Hematology|February 16, 2013
Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)S Neumann, S W Krause, G Maschmeyer, et al.
Annals of Hematology|December 6, 2001
Small bowel obstruction in acute myelogenous leukemia: stenosis or paralysis?M von Lilienfeld-Toal, O Ebert, I Theuerkauf, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 31, 2006
Change of procalcitonin predicts clinical outcome of febrile episodes in patients with hematological malignanciesM von Lilienfeld-Toal, A Schneider, K Orlopp, et al.
ESMO Open|April 12, 2025
Letter re: Ethnic origin in cancer clinical trials: overrated or understated?-A comprehensive analysis of cancer clinical trials leading to FDA and EMA approvals between 2020 and 2022M von Lilienfeld-Toal, S Agkatsev, A Glasmacher, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|September 6, 2005
An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patientsA Glasmacher, M von Lilienfeld-Toal, S Schulte, et al.
Infection|January 15, 2008
An audit of efficacy and toxicity of teicoplanin versus vancomycin in febrile neutropenia: is the different toxicity profile clinically relevant?C Hahn-Ast, A Glasmacher, A Arns, et al.
Clinical and Experimental Immunology|June 1, 2006
Activated gammadelta T cells express the natural cytotoxicity receptor natural killer p 44 and show cytotoxic activity against myeloma cellsM von Lilienfeld-Toal, J Nattermann, G Feldmann, et al.
Pageof 4